Login to Your Account



Facing Rising Costs For Clinical Trials, Rigel Offering Raises $57M

By Aaron Lorenzo


Monday, February 23, 2004
Raking in net proceeds of $57 million, Rigel Pharmaceuticals Inc. more than doubled its cash reserves after pricing a common stock offering. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription